Vicapsys Life Sciences, Inc. (VICP) 股价，以美元计价

ViCapsys, based in Athens, GA, is a development stage biotechnology company that is advancing a proprietary localized immune modulator. ViCapsys’s technology allows physicians to control the body’s immune system in regional areas around an implant, which reduces the risk of transplant rejection or fibrotic overgrowth due to foreign body recognition. The product offers wide ranging benefits in multiple surgical applications including, organ transplants, medical device implantations, and wound healing, without the need for systemic immune suppression. ViCapsys is currently investigating three initial pipeline products treating type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation. The company intends to develop and license other technologies related to immune modulation going forward.